In honor of Multiple Myeloma Awareness Month, we sat down with Dr. Hamza Hashmi, a hematologist-oncologist from Memorial Sloan Kettering Cancer Center, to understand how his family’s personal experience with cancer has influenced his approach to treating and caring for patients living with myeloma and other plasma cell disorders. As an oncology specialist, Dr. Hashmi is accustomed to his friends and family turning to him for guidance or additional context when a loved one is diagnosed with cancer, as they seek ways to cope with the situation. His siblings are also physicians, and they often re ..read more

Over the past decade, the rapid advancement of immunotherapies has been revolutionary in several cancers. However, pancreatic ductal adenocarcinoma, or PDAC, has been described as a “cold tumor” where immunosuppression results in low T-cell infiltration and poor treatment responses to immunotherapy. PDAC is an aggressive form of cancer with an average 5-year survival rate of less than 10% and a nearly 90% rate of recurrence. In a 2017 publication1, Dr. Vinod Balachandran, surgical oncologist at Memorial Sloan Kettering Cancer Center (MSKCC), worked with Adaptive to leverage our T-cell receptor ..read more

December 1, 2023 Clinically Actionable Insights: A Q&A with Dr. Luciano Costa on the Final Analysis of MASTER Luciano Costa, MD, PhD, Associate Director for Clinical Research at O’Neal Comprehensive Cancer Center & Susan Bobulsky, SVP, Diagnostics, clonoSEQ In 2021, Susan Bobulsky sat down with Dr. Luciano Costa to learn about the initial results from the phase 2 MRD response-Adapted Sequential ThERapy (MASTER) trial. The trial evaluated daratumumab (Darzalex), carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Dara-KRd) as induction therapy in patients with ..read more

August 4, 2023 Immune Medicine in Action: How Adaptive Immunosequencing Helped Validate a Personalized Vaccine Trial in PDAC Harlan Robins, PhD, Chief Scientific Officer and Co-founder Over the past decade, the rapid advancement of immunotherapies has been revolutionary in several cancers. However, pancreatic ductal adenocarcinoma, or PDAC, has been described as a “cold tumor” where immunosuppression results in low T-cell infiltration and poor treatment responses to immunotherapy. PDAC is an aggressive form of cancer with an average 5-year survival rate of less than 10% and a nearly 90 ..read more

March 22, 2023 Hope restored: The critical role that Minimal Residual Disease can play in blood cancer patient care Every March, people and organizations celebrate Multiple Myeloma Awareness Month – using their voices to raise awareness about efforts to diagnose, treat, and support patients with multiple myeloma as well as inspire others on their blood cancer journeys. Earlier this month, Adapters had the privilege of hearing from Tiffany Williams, a 55-year-old multiple myeloma patient. Tiffany is a retired pediatric nurse practitioner turned patient advocate. More than that – she’s a mo ..read more

February 21, 2023 Among Multiple Myeloma Patients Receiving MRD Testing, Majority Report Meaningful Benefits Susan Bobulsky, SVP, Diagnostics, clonoSEQ The uncertainty associated with a multiple myeloma diagnosis can often be deeply frightening. Many patients and their loved ones find themselves overwhelmed searching for information about prognosis and treatment. Others may feel anxious not knowing whether their treatment is working, or, if in remission, whether the cancer may come back. This is why minimal residual disease (MRD) testing is so important. MRD testing can help to provide ..read more

May 18, 2022 The Adaptive Internship Experience: A Perspective from Sydney W. Sydney W., former Adaptive intern During the summer and fall of 2020, I had the great pleasure of working as a digital marketing and communications associate on Adaptive Biotechnologies’ Corporate Marketing and Communications Team. My role consisted of creating content to communicate the science behind the company’s immune medicine platform – using social media to share that information broadly.  During my time at Adaptive, I came to learn the inextricable connection between clinical medicine, biotechnol ..read more

March 29, 2022 Recognizing the accomplishments of women in science: A conversation with Ana Bolivar, 2021 immunoSEQ® WISE award winner Adaptive Corporate Marketing and Communications​ Ana Bolivar, PhD Candidate We recently spoke with last year’s Women in Immune Science (WISE) award winner, Ana Bolivar, a PhD candidate in Dr. Eduardo Vilar’s lab at the University of Texas MD Anderson Cancer Center who received a $15,000 grant from Adaptive to support her research. Ana’s research focuses on Lynch Syndrome, an inherited cancer syndrome that affects >1 million Americans. Ana spoke with u ..read more

September 29, 2022 A Reflection on Blood Cancer Awareness Month: Patient Spotlight Sarah Foster, Sr. Director Marketing, Oncology Diagnostics As September and Blood Cancer Awareness Month wrap up, we want to reflect on a memorable conversation with Karen Thomas, a woman who received clonoSEQ® testing, and her physician, Dr. Hazma Hashmi, a hematologist-oncologist from the Medical University of South Carolina. At Adaptive, we know our diagnostic tests provide key information that help physicians and patients make treatment decisions, but we relish the opportunity to speak with them firs ..read more

September 15, 2022 Award Winning Immune Science: Meet Adaptive’s Latest Award Recipients Adaptive Corporate Affairs & Communications It is awards season here at Adaptive and we are continuously dedicated to promoting the work and accomplishments of scientists pursuing exciting research projects in immunology and other related fields with potential implications towards advancements in immunology. We believe more perspectives and diversity not only helps us as a company, but also helps advance the field of immune medicine overall, with the potential to improve millions of lives along ..read more